Myriad Genetics/MYGN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Myriad Genetics

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight.

Ticker

MYGN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Paul Diaz

Employees

2,700

Headquarters

Salt lake city, United States
Website
myriad.com

Myriad Genetics Metrics

BasicAdvanced
$2.1B
Market cap
-
P/E ratio
-$2.82
EPS
1.96
Beta
-
Dividend rate
$2.1B
1.95763
$25.95
$13.82
717K
1.987
1.819
5.092
5.092
-225.20%
-20.58%
-29.41%
-23.57%
2.661
2.71
15.594
11.44%
-56.30%

What the Analysts think about Myriad Genetics

Analyst Ratings

Majority rating from 12 analysts.
Buy

Myriad Genetics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-12.85% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$202M
2.85%
Net income
-$26M
-16.67%
Profit margin
-12.85%
-18.98%

Myriad Genetics Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 90.47%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.08
-$0.03
$0.04
-$0.01
-
Expected
-$0.09
-$0.08
$0.01
-$0.10
-$0.01
Surprise
-5.88%
-63.01%
214.29%
-90.47%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Myriad Genetics stock?

Myriad Genetics (MYGN) has a market cap of $2.1B as of June 14, 2024.

What is the P/E ratio for Myriad Genetics stock?

The price to earnings (P/E) ratio for Myriad Genetics (MYGN) stock is 0 as of June 14, 2024.

Does Myriad Genetics stock pay dividends?

No, Myriad Genetics (MYGN) stock does not pay dividends to its shareholders as of June 14, 2024.

When is the next Myriad Genetics dividend payment date?

Myriad Genetics (MYGN) stock does not pay dividends to its shareholders.

What is the beta indicator for Myriad Genetics?

Myriad Genetics (MYGN) has a beta rating of 1.96. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Myriad Genetics stock price target?

The target price for Myriad Genetics (MYGN) stock is $24.82, which is NaN% below the current price of $. This is an average based on projections from 11 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Myriad Genetics stock

Buy or sell Myriad Genetics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing